<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718337</url>
  </required_header>
  <id_info>
    <org_study_id>Postpartum IUD insertion</org_study_id>
    <nct_id>NCT04718337</nct_id>
  </id_info>
  <brief_title>Postpartum Intra-caesarean Intrauterine Device Insertion Using a Novel Technique</brief_title>
  <official_title>Postpartum Intra-caesarean Intrauterine Device Insertion Using a Novel Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The assessment of efficacy and patient safety of immediate postpartum IUD insertion using a&#xD;
      novel technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The postpartum period is so critical time for both the mother and newborn that needs special&#xD;
      health care because there are high morbidity and mortality rates during it (1).&#xD;
&#xD;
      The World Health Organization (WHO) recommends that a woman should wait at least 24 months&#xD;
      after delivery before the next pregnancy to decrease the adverse maternal, perinatal ,and&#xD;
      infant outcomes (2, 3).&#xD;
&#xD;
      A woman's fertility may begin to return rapidly and ovulate within 4:6 weeks postpartum&#xD;
      particularly if she is not exclusively breastfeeding. In addition , more than 50% of women&#xD;
      become sexually active by 6 weeks postpartum (4, 5).&#xD;
&#xD;
      So, it is important to provide highly effective contraception immediately after delivery&#xD;
      before leaving the delivery setting especially in communities where women cannot return&#xD;
      easily for follow up visits due to financial and social barriers or who have limited access&#xD;
      to medical service (6, 7).&#xD;
&#xD;
      The use of effective postpartum contraception particularly longـacting reversible&#xD;
      contraception (LARC) methods like the intrauterine device (IUD) has been shown to decrease&#xD;
      the risk of unintended pregnancy and its complications and avoid repeated caesarean sections&#xD;
      with higher continuation rates of use than other methods 6 months after delivery (8-10).&#xD;
&#xD;
      Immediate post placental intraـcaesarean IUD insertion has many advantages as it is effective&#xD;
      reversible longـterm contraception, doesn't interfere with breastfeeding, is coitus&#xD;
      independent and the woman can avoid discomfort and pain during the standard insertion and&#xD;
      bleeding from insertion will be masked by lochia (11-14).&#xD;
&#xD;
      Studies have shown that with effective provider training, the immediate postpartum IUD&#xD;
      insertion (IPPIUD) complications such as expulsion, pelvic infection, bleeding, pain, missing&#xD;
      threads ,and failure rates are not significantly different from those of interval PPIUD&#xD;
      insertion (4:6 weeks) after delivery (15, 16).&#xD;
&#xD;
      By using a novel technique in this study, these complications would be decreased.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of postpartum intra-caesaren IUD insertion</measure>
    <time_frame>6 months</time_frame>
    <description>the evaluation of efficacy of this novel technique to decrease the rates of expulsion, missing threads and failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient safety of postpartum intra-caesarean IUD insertion</measure>
    <time_frame>6 months</time_frame>
    <description>the evaluation of patient safety including pelvic infections, lower abdominal pain and excessive bleeding.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">75</enrollment>
  <condition>IUD Complication</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women admitted to undergo CS.&#xD;
&#xD;
          2. Singleton pregnancy.&#xD;
&#xD;
          3. Delivery of a liveـborn infant with gestational age &lt; 36 weeks.&#xD;
&#xD;
          4. Informed and written consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of dysmenorrhea, menorrhagia or coagulopathies.&#xD;
&#xD;
          2. Uterine anomalies or fibroids.&#xD;
&#xD;
          3. Antepartum or intrapartum hemorrhage.&#xD;
&#xD;
          4. Prolonged rupture of membranes &lt;24 hours with or without chorioamnionitis.&#xD;
&#xD;
          5. Intrapartum fever.&#xD;
&#xD;
          6. History of current, recent (within previous 3 months) or recurrent pelvic&#xD;
             infilammatory diseases (PID).&#xD;
&#xD;
          7. History of ectopic pregnancy.&#xD;
&#xD;
          8. Multiple pregnancy.&#xD;
&#xD;
          9. Active cervicitis, vaginitis or sexual transmitted diseases (STD) on gyaecological&#xD;
             examination.&#xD;
&#xD;
         10. Allergy to any component of the IUD or Wilson's disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christine T Laisha</last_name>
    <phone>01069194366</phone>
    <phone_ext>0882500729</phone_ext>
    <email>christinetamer987@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahmoud SM Zakhera</last_name>
    <phone>01069128680</phone>
    <email>mszakhera@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Kumar M, Kumar M, Aggarwal P, Gangania A, Dewan. A study to evaluate and compare the expulsion and continuation rates of post placental insertion of Cu 375 and CuT 380A in Indian women at a premier hospital in New Delhi, India. Int J Reprod Contracept Obstet Gynecol 2017;6(9):3992-4000. Health WHODoM, Abuse S, Organization WH, Health WHODoM, Health SAM, Evidence WHOMH, et al. Mental health atlas 2005: World Health Organization; 2005. Rutstein S, Johnson K, Conde-Agudelo A, Rosas-Bermudez A. Effect of birth spacing on infant and child mortality: a systematic review and meta-analysis. WHO Technical Consultation and Scientific Review of Birth Spacing 2005;13(5). Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol 2011;117(3):657-662. Speroff L, Mishell DR. The postpartum visit: it's time for a change in order to optimally initiate contraception. Contraception 2008;78(2):90-98. Lucksom PG, Kanungo BK, Sebastian N, Mehrotra R, Pradhan D, Upadhya R. Comparative study of interval versus postpartum Cu-T insertion in a central referral hospital of North East India. Int J Reprod Contracept Obstet Gynecol 2015;4(1):47-51. DiBari JN, Yu SM, Chao SM, Lu MC. Use of postpartum care: predictors and barriers. Journal of pregnancy 2014;2014. Levi EE, Stuart GS, Zerden ML, Garrett JM, Bryant AG. Intrauterine device placement during cesarean delivery and continued use 6 months postpartum: a randomized controlled trial. Obstet Gynecol 2015;126(1):5-11. Organization WH. Report of a WHO technical consultation on birth spacing: Geneva, Switzerland 13-15 June 2005. World Health Organization; 2007. Obstetricians ACo, Obstetrics GJ, gynecology. ACOG Practice Bulletin No. 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstetrics and Gynecology. 2011;118(1):184-196. Kapp N, Curtis KM. Intrauterine device insertion during the postpartum period: a systematic review. Contraception 2009;80(4):327-336. Glasier A. Best Practice in Postpartum Family Planning. Best Practice Paper No 1. June 2015. London: Royal College of Obstetricians and Gynaecologists; 2015. Heller R, Cameron S, Briggs R, Forson N, Glasier A. Postpartum contraception: a missed opportunity to prevent unintended pregnancy and short inter-pregnancy intervals. J Fam Plann Reprod Health Care 2016;42(2):93-98. Teal SB. Postpartum contraception: optimizing interpregnancy intervals. Contraception 2014;89(6):487-488. Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Stanwood NL. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev 2010;(5):CD003036. Çelen Ş, Sucak A, Yıldız Y, Danışman N. Immediate postplacental insertion of an intrauterine contraceptive device during cesarean section. Contraception 2011;84(3):240-243. Zaconeta AM, Oliveira AC, Estrela FS, Vasconcelos TM, França PS, Wanderley MdS, Amato AA. Intrauterine device insertion during cesarean section in women without prenatal contraception counseling: lessons from a country with high cesarean rates. Revista Brasileira de Ginecolgia e Obstetricia 2019;41(8):485-492.</citation>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 26, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>January 16, 2021</last_update_submitted>
  <last_update_submitted_qc>January 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Christine Tamer Laisha</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

